Last reviewed · How we verify
Cygro (MADURAMICIN)
Cygro works by binding to the 5-hydroxytryptamine receptor 6, a subtype of serotonin receptor.
Cygro, also known as Maduramicin, is a small molecule modality targeting the 5-hydroxytryptamine receptor 6. Its exact drug class is unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential applications of Cygro. Its development history is also unclear, with no information available on its original developer or current owner.
At a glance
| Generic name | MADURAMICIN |
|---|---|
| Target | 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Mechanism of action
Imagine your brain has many different locks, and serotonin is the key that fits into some of those locks. Cygro is a special key that fits into one of those locks, called the 5-hydroxytryptamine receptor 6. By binding to this lock, Cygro can affect how your brain cells communicate with each other.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cygro CI brief — competitive landscape report
- Cygro updates RSS · CI watch RSS